Please use this identifier to cite or link to this item:
Title: Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2).
Authors: Barlow, A. D.
Xie, J.
Moore, C. E.
Campbell, S. C.
Shaw, J. A.
Nicholson, M. L.
Herbert, T. P.
First Published: 8-Feb-2012
Publisher: Springer Verlag (Germany)
Citation: Diabetologia, 2012, 55 (5), pp. 1355-1365
Abstract: Rapamycin (sirolimus) is one of the primary immunosuppressants for islet transplantation. Yet there is evidence that the long-term treatment of islet-transplant patients with rapamycin may be responsible for subsequent loss of islet graft function and viability. Therefore, the primary objective of this study was to elucidate the molecular mechanism of rapamycin toxicity in beta cells.
DOI Link: 10.1007/s00125-012-2475-7
ISSN: 0012-186X
eISSN: 1432-0428
Type: Journal Article
Rights: Copyright The Author(s) 2012. This article is published with open access at This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Description: The online version of this article (doi:10.1007/s00125-012-2475-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
File Description SizeFormat 
art%3A10.1007%2Fs00125-012-2475-7.pdfPublisher version469.58 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.